Thomas M Cascino1, Michelle M Kittleson2, Anuradha Lala3, Josef Stehlik4, Maryse Palardy1, Salpy V Pamboukian5, Gregory A Ewald6, Maria M Mountis7, Douglas A Horstmanshof8, Shawn W Robinson9, Palak Shah10, Ulrich P Jorde11, Rhondalyn C McLean12, Blair Richards13, Shokoufeh Khalatbari13, Cathie Spino13,14, Wendy C Taddei-Peters15, Kathleen L Grady16, Douglas L Mann6, Lynne W Stevenson17, Garrick C Stewart18, Keith D Aaronson1. 1. Division of Cardiovascular Disease, University of Michigan, Ann Arbor (T.M.C., M.P., K.D.A.). 2. Smidt Heart Institute, Cedars-Sinai, Los Angeles, CA (M.M.K.). 3. Mount Sinai Hospital, New York, NY (A.L.). 4. University of Utah Health, Salt Lake City (J.S.). 5. University of Alabama at Birmingham (S.V.P.). 6. Washington University School of Medicine, St. Louis, MO (G.A.E., D.L.M.). 7. Cleveland Clinic, OH (M.M.M.). 8. INTEGRIS Baptist Medical Center, Oklahoma City, OK (D.A.H.). 9. University of Maryland, Baltimore (S.W.R.). 10. Inova Heart and Vascular Institute, Falls Church, VA (P.S.). 11. Montefiore Medical Center, Bronx, NY (U.P.J.). 12. University of Pennsylvania, Philadelphia (R.C.M.). 13. Michigan Institute for Clinical and Health Research, University of Michigan, Ann Arbor (B.R., S.K., C.S.). 14. University of Michigan School of Public Health, Ann Arbor (C.S.). 15. National Heart, Lung, and Blood Institute, Bethesda, MD (W.C.T.-P.). 16. Northwestern University, Chicago, IL (K.L.G.). 17. Vanderbilt University, Nashville, TN (L.W.S.). 18. Brigham and Women's Hospital, Boston, MA (G.C.S.).
Abstract
BACKGROUND: Patients with heart failure (HF) often have multiple chronic conditions that may impact health-related quality of life (HRQOL) despite HF therapy. We sought to determine the association between noncardiac comorbidities and HRQOL in ambulatory patients with advanced HF. METHODS: Baseline data from 373 subjects in REVIVAL (Registry Evaluation of Vital Information for Ventricular Assist Devices in Ambulatory Life) were analyzed using multivariable general linear models to evaluate the relationship between comorbidities and HRQOL (EuroQol Visual Analogue Scale, EQ-5D-3L Index Score, and Kansas City Cardiomyopathy Questionnaire). The primary independent variables were a comorbidity index (sum of 14 noncardiac conditions), a residual comorbidity index (without depression), and depression alone. The median (25th to 75th percentile) number of comorbidities was 3 (2-4). RESULTS: Increasing comorbidity burden was associated with a reduction in generic (EQ-5D Index, P=0.005) and HF-specific (Kansas City Cardiomyopathy Questionnaire, P=0.001) HRQOL. The residual comorbidity index was not associated with HRQOL when depression included in the model independently, while depression was associated with HRQOL across all measures. Participants with depression (versus without) scored on average 13 points (95% CI, 8-17) lower on the EuroQol Visual Analogue Scale, 0.15 points (95% CI, 0.12-0.18) lower on the EQ-5D Index, and 24.9 points (95% CI, 21.2-28.5) lower on the Kansas City Cardiomyopathy Questionnaire overall summary score. CONCLUSIONS: While noncardiac comorbidities were prevalent in ambulatory advanced HF patients, only depression was associated with decreased generic and HF-specific HRQOL. Other than depression, the presence of noncardiac comorbidities should not impact expected gains in HRQOL following ventricular assist device implantation, provided the conditions are not a contraindication to implant. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01369407.
BACKGROUND:Patients with heart failure (HF) often have multiple chronic conditions that may impact health-related quality of life (HRQOL) despite HF therapy. We sought to determine the association between noncardiac comorbidities and HRQOL in ambulatory patients with advanced HF. METHODS: Baseline data from 373 subjects in REVIVAL (Registry Evaluation of Vital Information for Ventricular Assist Devices in Ambulatory Life) were analyzed using multivariable general linear models to evaluate the relationship between comorbidities and HRQOL (EuroQol Visual Analogue Scale, EQ-5D-3L Index Score, and Kansas City Cardiomyopathy Questionnaire). The primary independent variables were a comorbidity index (sum of 14 noncardiac conditions), a residual comorbidity index (without depression), and depression alone. The median (25th to 75th percentile) number of comorbidities was 3 (2-4). RESULTS: Increasing comorbidity burden was associated with a reduction in generic (EQ-5D Index, P=0.005) and HF-specific (Kansas City Cardiomyopathy Questionnaire, P=0.001) HRQOL. The residual comorbidity index was not associated with HRQOL when depression included in the model independently, while depression was associated with HRQOL across all measures. Participants with depression (versus without) scored on average 13 points (95% CI, 8-17) lower on the EuroQol Visual Analogue Scale, 0.15 points (95% CI, 0.12-0.18) lower on the EQ-5D Index, and 24.9 points (95% CI, 21.2-28.5) lower on the Kansas City Cardiomyopathy Questionnaire overall summary score. CONCLUSIONS: While noncardiac comorbidities were prevalent in ambulatory advanced HF patients, only depression was associated with decreased generic and HF-specific HRQOL. Other than depression, the presence of noncardiac comorbidities should not impact expected gains in HRQOL following ventricular assist device implantation, provided the conditions are not a contraindication to implant. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01369407.
Entities:
Keywords:
depression; heart failure with reduced ejection fraction; heart-assist devices; quality of life
Authors: John Spertus; Eric Peterson; Mark W Conard; Paul A Heidenreich; Harlan M Krumholz; Philip Jones; Peter A McCullough; Ileana Pina; Joseph Tooley; William S Weintraub; John S Rumsfeld Journal: Am Heart J Date: 2005-10 Impact factor: 4.749
Authors: Haider J Warraich; Larry A Allen; Laura J Blue; Erin L Chaussee; Jocelyn S Thompson; Colleen K McIlvennan; Kelsey M Flint; Daniel D Matlock; Chetan B Patel Journal: Am Heart J Date: 2019-04-25 Impact factor: 4.749
Authors: Mary Amanda Dew; Andrea F DiMartini; Fabienne Dobbels; Kathleen L Grady; Sheila G Jowsey-Gregoire; Annemarie Kaan; Kay Kendall; Quincy-Robyn Young; Susan E Abbey; Zeeshan Butt; Catherine C Crone; Sabina De Geest; Christina T Doligalski; Christiane Kugler; Laurie McDonald; Linda Ohler; Liz Painter; Michael G Petty; Desiree Robson; Thomas Schlöglhofer; Terry D Schneekloth; Jonathan P Singer; Patrick J Smith; Heike Spaderna; Jeffrey J Teuteberg; Roger D Yusen; Paula C Zimbrean Journal: J Heart Lung Transplant Date: 2018-04-27 Impact factor: 10.247
Authors: Randall C Starling; Jerry D Estep; Douglas A Horstmanshof; Carmelo A Milano; Josef Stehlik; Keyur B Shah; Brian A Bruckner; Sangjin Lee; James W Long; Craig H Selzman; Vigneshwar Kasirajan; Donald C Haas; Andrew J Boyle; Joyce Chuang; David J Farrar; Joseph G Rogers Journal: JACC Heart Fail Date: 2017-04-05 Impact factor: 12.035
Authors: Anneleen Baert; Delphine De Smedt; Johan De Sutter; Dirk De Bacquer; Paolo Emilio Puddu; Els Clays; Sofie Pardaens Journal: Eur J Prev Cardiol Date: 2018-01-31 Impact factor: 7.804
Authors: Keith D Aaronson; Garrick C Stewart; Francis D Pagani; Lynne W Stevenson; Maryse Palardy; Dennis M McNamara; Donna M Mancini; Kathleen Grady; John Gorcsan; Robert Kormos; Neal Jeffries; Wendy C Taddei-Peters; Blair Richards; Shokoufeh Khalatbari; Cathie Spino; J Timothy Baldwin; Douglas L Mann Journal: J Heart Lung Transplant Date: 2019-09-14 Impact factor: 10.247